vincristine / Generic mfg. - LARVOL DELTA

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. (PubMed, N Engl J Med) - P3 | "Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP. (Funded by F. Hoffmann-La Roche/Genentech; POLARIX ClinicalTrials.gov number, NCT03274492.)."

Journal • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD79B

The effect of compression therapy using surgical gloves on (R-)CHOP therapy induced peripheral neuropathy(randomized control trial) (clinicaltrials.gov) - P=N/A | N=103 | Completed | Sponsor: Hitachi general hospital; Kanmon medical center | Unknown status ➔ Completed

Trial completion • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study. (PubMed, Br J Haematol) - P1 | "Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R-CHOP) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) who had ≥1 prior obinutuzumab/rituximab-containing therapy (NCT03467373). Median progression-free survival was not reached after 44.2 months follow-up. Glofitamab plus G/R-CHOP showed promising benefit in relapsed/refractory B-NHL, supporting future investigation of glofitamab (2.5/10/30 mg) with R-CHOP in untreated diffuse large B-cell lymphoma."

Journal • P1 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Fatigue • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL. (PubMed, Blood Neoplasia) - P3 | "We aimed to define the key lymphoma microenvironment factors associated with clinical outcomes in patients treated with anti-CD20 (rituximab or obinutuzumab) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; anti-CD20 + CHOP) and to understand how treatment with a modified, ADC-containing chemoimmunotherapy regimen alters the influence of the pretreatment immune landscape on clinical outcome. Our results indicate that ADCs may provide therapeutic benefit to patients with unfavorable immune microenvironments. These trials were registered at www.clinicaltrials.gov as #NCT01287741, #NCT00486759, and #NCT03274492."

Biomarker • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma. (ASCO 2022) - P1/2 | "Background: Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), but a third of patients (pts) experience treatment failure. LOCHOP demonstrates high efficacy and tolerability in newly diagnosed DLBCL, leading to a high rate of undetectable minimal residual disease by ctDNA. Noninvasive molecular subtyping is feasible as a supplement to tissue diagnosis and should be incorporated in future studies aiming to improve on RCHOP."

Circulating tumor DNA • P1/2 data • Cardiovascular • Diffuse Large B Cell Lymphoma • Fatigue • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • Venous Thromboembolism

Aggressive Clinical Course and Treatment Refractoriness in Marginal Zone Lymphoma: A Case Report (SOHO 2026) - "The patient received 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This case highlights that, despite its usual indolent behavior, MZL may rarely present with aggressive features and early refractoriness to first-line chemoimmunotherapy. Rapid progression, bulky disease, hemolytic anemia, and tumor lysis features should prompt reassessment for aggressive biology or histologic transformation. Obinutuzumab plus bendamustine may represent an effective therapeutic option in selected patients with relapsed or refractory MZL."

Case report • Clinical • IO biomarker • B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCND1 • MME

Early Chemorefractory Progression in TP53-Deleted Chronic Lymphocytic Leukemia: A Case Highlighting the Need for Targeted Therapy (SOHO 2026) - "The patient initially received 2 cycles of rituximab-bendamustine, followed by 1 cycle of R-CHOP because of ongoing clinical concern for active disease...Based on the patient's molecular profile and resistance to conventional therapy, treatment with acalabrutinib plus obinutuzumab was planned... A 66-year-old man was diagnosed with CLL based on peripheral blood immunophenotyping showing a typical clonal B-cell population positive for CD19, CD5, and CD23, with weak CD20 expression and kappa light-chain restriction. Serum immunofixation also demonstrated a kappa monoclonal band. Cytogenetic evaluation with FISH revealed 17p13.1 (TP53) deletion in all analyzed cells, indicating a veryhigh-risk disease profile."

Clinical • IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD20 • CD5 • FCER2 • TP53

Marrow-Dominant Aggressive Progression of TP53-Altered CLL/SLL After Reactive Myelofibrosis: A Diagnostic and Therapeutic Challenge (SOHO 2026) - "Treatment was complicated only by transient grade 4 neutropenia, recovering within 3–5 days with filgrastim...Ruxolitinib was started with initial count normalization...The patient received 1 cycle of obinutuzumab plus DHAP... This case highlights marrow-dominant aggressive progression of high-risk CLL/SLL after reactive myelofibrosis, creating a clinically relevant diagnostic dilemma between blastoid CLL/SLL progression and Richter transformation. It underscores the need for integrated morphologic, immunophenotypic, molecular, and clinical assessment, especially where limited access to targeted therapy influences disease trajectory and treatment selection. CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; CLL: chronic lymphocytic leukemia; COVID-19: coronavirus disease 2019; DHAP: dexamethasone, cytarabine, and cisplatin; IGHV: immunoglobulin heavy chain variable region; JAK2: Janus kinase 2; SLL: small lymphocytic lymphoma; TP53: tumor protein p53."

Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelofibrosis • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • IGH • JAK2 • TP53

Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA. (PubMed, Clin Lymphoma Myeloma Leuk) - "PET-derived TMTV has prognostic value in identifying patients at risk of early treatment failure."

Journal • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • MYC

Antigen Escape in Relapsed/Refractory Large B-Cell Lymphoma: A Case Series of CD20 Expression Loss After CD20-Directed Therapy (SOHO 2026) - "Context: CD20-directed therapy remains foundational in the management of LBCL, yet relapsed disease may emerge with loss of CD20 expression, limiting the utility of rituximab- or obinutuzumab-based regimens or bispecific antibodies...All patients had received prior CD20-directed therapy, most commonly rituximab-containing regimens, including R-CHOP, REPOCH, R-GemOx, R-ICE, rituximab-lenalidomide, or bendamustine-rituximab. Several also received contemporary salvage approaches, including polatuzumab-based therapy, epcoritamab, tafasitamab-lenalidomide, radiation, lymphodepleting chemotherapy, and CAR-T therapy with axicabtagene ciloleucel or tisagenlecleucel... CD20-negative conversion is a clinically consequential pattern of relapse in heavily pretreated LBCL. This series highlights the importance of repeat biopsy at progression to reassess targetable antigen expression and avoid ineffective recycling of CD20-directed therapy. Antigen reassessment should inform..."

Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20 • CD22

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study. (PubMed, J Clin Oncol) - P3 | "MRD status can determine outcome after induction and during maintenance, and MRD negativity is a prerequisite for long-term disease control in FL. The higher MRD responses after G- versus R-based treatment confirm more effective tumor cell clearance."

Biomarker • Journal • Minimal residual disease • P3 data • Residual disease • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. (PubMed, Blood Adv) - P1/2 | "Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy (R-CHOP), but a third of patients experience refractory or relapsed disease after frontline R-CHOP. LO-CHOP demonstrates high efficacy and tolerability in newly diagnosed DLBCL, leading to a high rate of undetectable minimal residual disease by ctDNA by end of therapy. This trial is registered at www.clinicaltrials.gov as NCT02529852."

Journal • P1/2 data • Diffuse Large B Cell Lymphoma • Fatigue • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia

Complete Metabolic Response to Pirtobrutinib in Refractory Richter Transformation (SOHO 2026) - "Venetoclax and obinutuzumab (VO) therapy was initiated...Acalabrutinib was stopped, and zanubrutinib was started 2 months later...He is now being started on epcoritamab as a bridge to ASCT... This case highlights the very uncommon finding of RT presenting as isolated splenomegaly. SF3B1 mutations have not been well characterized in RT; this case could contribute to the evolving understanding of the mutational landscape of RT. It was impressive to see a complete response (CR) with pirtobrutinib in RT in a patient refractory to chemoimmunotherapy, although only 13% achieved CR in the BRUIN study."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • ATM • SF3B1

OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY (EHA 2022) - P3 | "Pts were randomized 1:1 to receive G 1000mg intravenously (IV; Days [D]1, 8 and 15 of Cycle 1 and D1 of subsequent cycles) or R 375mg/m 2 IV (D1 of each cycle) plus chemo for 6 or 8 cycles depending on the chemo backbone selected at each institution (cyclophosphamide, doxorubicin, vincristine, and prednisolone [CHOP]; cyclophosphamide, vincristine, and prednisolone [CVP]; or bendamustine). These safety findings are consistent with previous analyses. Conclusion After a median observation time of 8 years, a meaningful improvement in PFS was maintained with G-chemo versus R-chemo in pts with previously untreated FL, confirming the role of G-chemo as a standard of care for the first-line treatment of pts with FL."

Clinical • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Oncology • Pneumonia • Respiratory Diseases

Unusual pelvic mass in a young adult: prostatic Ewing's sarcoma with distant metastases. (PubMed, BMJ Case Rep) - "The patient underwent urinary and bowel diversion, followed by Vincristine, Adriamycin, Cyclophosphamide alternating with Ifosfamide and Etoposide (VAC/IE) chemotherapy. He achieved complete metabolic remission, allowing colostomy reversal and is currently under surveillance. This case illustrates the need to consider rare sarcomas in the differential diagnosis of pelvic masses in young men with normal serum PSA and highlights the potential for durable response with timely systemic therapy."

Journal • Constipation • Ewing Sarcoma • Gastroenterology • Gastrointestinal Disorder • Genito-urinary Cancer • Oncology • Pain • Prostate Cancer • Sarcoma • Solid Tumor • CD99 • FLI1

Secondary Acute T-Lymphoblastic Leukemia Following Pregnancy After Remission of Acute Promyelocytic Leukemia: A Case Report with Literature Review. (PubMed, Ann Clin Lab Sci) - "Herein, we present a case of a young female with APL who attained complete remission (CR) after receiving dual induction therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), followed by standard consolidation and maintenance treatment cycles...She attained a second CR after receiving the VDCLP chemotherapy regimen (vincristine+daunorubicin+cyclophosphamide+L-asparaginase+prednisone). She subsequently underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) and remained in sustained CR at the 18-month follow-up time point. For patients with T-ALL secondary to APL after treatment remission, early diagnosis combined with the VDCLP regimen and allo-HSCT demonstrated certain therapeutic efficacy."

Journal • Review • Acute Promyelocytic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • Transplantation

Clinical Outcomes of Reduced-Dose Whole-Brain Radiotherapy After Induction Chemotherapy for Primary Central Nervous System Lymphoma: A Retrospective Single-Institution Study (ASTRO 2026) - "Induction chemotherapy consisted of R-MPV (rituximab, methotrexate, procarbazine, and vincristine) up to seven cycles, followed by two cycles of high-dose cytarabine administered as consolidation after radiotherapy. Reduced-dose WBRT following induction chemotherapy provided durable disease control and favorable survival outcomes in a real-world PCNSL cohort. These findings support rdWBRT as an effective consolidative strategy. Further investigation of neurocognitive outcomes is warranted."

Clinical data • Retrospective data • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Response-Directed Radiotherapy after Methotrexate-Based Systemic Therapy for Patients with Primary CNS Lymphoma (ASTRO 2026) - "The most common ST regimen was HD-MTX, Procarbazine, and Vincristine (MPV) +/- Rituximab (R) in 32/52 (62%) of pts, while 13/52 (25%) received HD-MTX +/- R, and 7/52 (13%) received other HD-MTX-based regimens. 16/52 pts (31%) received consolidative cytarabine... In pts with PCNSL treated with HD-MTX-based ST, an RT approach incorporating a boost to residual disease is associated with improved PFS. Further investigation into optimal consolidative strategies in pts with a PR following HD-MTX-based induction is warranted."

Clinical • CNS Lymphoma • Eye Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Primary Vitreoretinal Lymphoma • Secondary Central Nervous System Lymphoma

Prospective Treatment of Types I, II, and III Pleuropulmonary Blastoma (PPB): A COG Groupwide Phase 3 Study (ARAR2331) (ASTRO 2026) - "For Types II and III, a novel "window" design assesses the objective response rate (CR+PR) to two initial cycles of vincristine, topotecan, and cyclophosphamide (VTC). Patients subsequently receive standard ifosfamide, vincristine, dactinomycin, and doxorubicin (IVADo) followed by consolidation based on window therapy response... As the inaugural prospective trial for Pleuropulmonary Blastoma, ARAR2331 possesses the potential to establish the definitive standard of care for this rare malignancy."

Clinical • P3 data • Lung Cancer • Oncology • Sarcoma • Solid Tumor • DICER1 • TP53

Leptomeningeal Failure in Pediatric Parameningeal Rhabdomyosarcoma: Predictive Factors and Opportunities for Prevention (ASTRO 2026) - "Chemotherapy included high dose (HD)-(vincristine [V], actinomycin [A], and cyclophosphamide [C; 2200 mg/m2]) (n=25), V, doxorubicin (D), C/ifosfamide (I), etoposide (E) (n=14), or lower cumulative cyclophosphamide dose regimens (n=9). LMD is the most common pattern of failure among patients with PM RMS with ICE. Novel treatment strategies for this patient population are needed to reduce the risk of LMD failure and improve clinical outcomes."

Biomarker • Clinical • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor

Reduced-Margin Radiotherapy in Young Children with Brain Tumors: A Long-Term Analysis (ASTRO 2026) - "Materials/ Between 2007 and 2017, 75 children with atypical teratoid rhabdoid tumor (ATRT=18), ependymoma (EP=32), and medulloblastoma (MB=25) underwent definitive radiotherapy (54 Gy to the primary site) using proton (n=36) or photon (n=39) therapy after four cycles of intravenous cyclophosphamide, vincristine, cisplatin, and methotrexate. Focal radiotherapy using a reduced 0.5 cm clinical target volume margin is feasible in selected young children with brain tumors with no observed marginal failures. Long-term disease control was achieved in a substantial proportion of patients supporting this risk-adapted approach to minimize radiotherapy exposure in very young children."

Clinical • Brain Cancer • Embryonal Tumor • Ependymoma • Medulloblastoma • Oncology • Rhabdoid Tumor • Sarcoma • Solid Tumor

Nanoliposomal irinotecan (nal-IRI) combined with Vincristine in Second-line Treatment of Advanced Soft Tissue Sarcoma : a Single-arm, Open-label, Dose-escalation Phase Ib Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P1 data • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Irinotecan Liposome Plus Vincristine and Apatinib for Relapsed/Refractory Adult Rhabdomyosarcoma: An Exploratory Study (ESMO 2026) - No abstract available

Clinical • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor

A Very Rarely Reported Case of Multifocal Intestinal Diffuse Large B-Cell Non-Hodgkinâs Lymphoma Presenting as a Concurrent Small and Large Bowel Obstruction (ACG 2026) - "For patients presenting with bowel obstruction due to DLBCL, treatment typically involves surgical resection followed most commonly by the R-CHOP chemotherapy regimen, consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Figure: Image 1. CT abdomen/pelvis showing a mass involving the small bowel loop within the right mid abdomen measuring 9.7 x 5.6 cm, as well as a lesion surrounding the hepatic flexure measuring 6.3 x 7.5 cm."

Clinical • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Small Intestinal Carcinoma • BCL2

Primary Hepatic Diffuse Large B-Cell Lymphoma Presenting as Obstructive Jaundice (ACG 2026) - "Rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP) therapy remains the standard of care in those with DLBCL. Biopsy and identification are key to treatment often with Rituximab based chemotherapy, which has a favorable prognosis. Interventional approaches such as ERCP stenting or biliary drains can be used to decompress the biliary system."

Acute Kidney Injury • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hepatology • Lymphoma • Non-Hodgkin’s Lymphoma • Renal Disease • BCL6